TXMD - TherapeuticsMD, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.580
-0.030 (-0.45%)
As of 11:39AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.610
Open6.510
Bid6.580 x 800
Ask6.590 x 1800
Day's Range6.482 - 6.620
52 Week Range4.340 - 7.660
Volume457,855
Avg. Volume3,144,449
Market Cap1.425B
Beta1.36
PE Ratio (TTM)N/A
EPS (TTM)-0.374
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
Trade prices are not sourced from all markets
  • ACCESSWIRE2 days ago

    Free Pre-Market Technical Recap on TherapeuticsMD and Three Additional Healthcare Stocks

    LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), TherapeuticsMD Inc. (NASDAQ: TXMD), and Zogenix Inc. (NASDAQ: ZGNX).

  • See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    Short interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. Over the last one-month, outflows of investor capital in ETFs holding TXMD totaled $1.88 billion.

  • See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    TherapeuticsMD Inc NASDAQ/NGS:TXMD

  • Business Wirelast month

    TherapeuticsMD Announces Draw Down of $75 Million Under Term Loan with MidCap Financial

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company has completed the first draw down of $75 million under its previously announced $200 million term loan facility with MidCap Financial, managed by Apollo Capital Management, L.P. The Company intends to use the proceeds from the financing to support the commercial launch of its recently approved product, Imvexxy™ (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women.

  • TherapeuticsMD (TXMD) Soars: Stock Adds 9.1% in Session
    Zackslast month

    TherapeuticsMD (TXMD) Soars: Stock Adds 9.1% in Session

    TherapeuticsMD (TXMD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • Business Wirelast month

    TherapeuticsMD to Present at Goldman Sachs 39th Annual Global Healthcare Conference

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company will present at the Goldman Sachs 2018 Global Healthcare Conference being held on June 12-14, 2018 in Rancho Palos Verdes, CA.

  • ACCESSWIRElast month

    Stock Performance Review on TherapeuticsMD and Three Other Healthcare Stocks

    LONDON, UK / ACCESSWIRE / June 6, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Healthcare stocks: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), Sanofi (NYSE: SNY), and TherapeuticsMD Inc. (NASDAQ: TXMD).

  • Business Wirelast month

    TherapeuticsMD Announces Multiple Presentations at the International Menopause Society’s 16th World Congress

    TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced the schedule of seven presentations at the International Menopause Society’s 16th World Congress on Menopause related to clinical data for Imvexxy™ , an applicator-free, ultra-low dose estradiol softgel vaginal insert, and TX-001HR, the Company’s investigational bio-identical oral combination of estradiol and progesterone ...

  • Here's Why TherapeuticsMD Inc Jumped Today
    Motley Foollast month

    Here's Why TherapeuticsMD Inc Jumped Today

    Shares rise after the company receives some bullish analyst praise. Here's what investors need to know.

  • Business Wirelast month

    TherapeuticsMD to Present at Jefferies 2018 Healthcare Conference

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company will present at the Jefferies 2018 Healthcare Conference being held on June 5-8, 2018. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: AbbVie and TherapeuticsMD

    NEW YORK, NY / ACCESSWIRE / June 4, 2018 / U.S. markets closed in the green on Friday, with the Dow rising more than 200 points on the strength of the May jobs report. Approximately 223,000 new jobs were ...

  • Business Wire2 months ago

    TherapeuticsMD Announces Clinical Abstract at the 2018 ASCO Annual Meeting

    TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced the availability of clinical data from the REJOICE trial for IMVEXXY™ .

  • SmarterAnalyst2 months ago

    What Scpharmaceuticals (SCPH) Investors Can Learn from the History

    The biotech company's shares are plunging at breakneck speed of almost 30%. Unfortunately for investors, SCPH has received a letter from the FDA identifying deficiencies in its Furoscix NDA that preclude discussion of labeling and postmarketing requirements/ commitments at this time. When the FDA identifies an issue (through initial review or through later submissions), the agency's most frequent next decision is the rejection of the drug under review.

  • Reuters2 months ago

    TherapeuticsMD's therapy for menopause-related condition gets approval

    Women's healthcare company TherapeuticsMD Inc won its first-ever U.S. approval on Wednesday with the drug regulator clearing its hormone therapy for a painful condition triggered by menopause after rejecting it a year earlier. The company's shares were volatile, oscillating between gains and losses.

  • PR Newswire2 months ago

    TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause

    BOCA RATON, Fla., May 30, 2018 /PRNewswire/ -- TherapeuticsMD, Inc. (TXMD), an innovative women's healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved IMVEXXY™ (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. IMVEXXY is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose, the 4 mcg representing the lowest approved dose of vaginal estradiol available.

  • Benzinga2 months ago

    TherapeuticsMD Announces FDA Approval Of IMVEXXY — For Real This Time

    Last week, TherapeuticsMD soared when a prematurely published marketing website for Imvexxy falsely touted the therapy as approved and prepped for sale. The company removed the website as soon as the market reacted, blamed the false news on media and confirmed that the FDA hadn’t yet ruled on the drug. Now, TherapeuticsMD has republished the same Imvexxy website and assured that the product is, in fact, approved.

  • Business Wire2 months ago

    TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, Due to Menopause

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. “IMVEXXY is a bio-identical vaginal estrogen product that offers a fraction of the estrogen contained in the average doses of many existing products currently on the market,” said Brian Bernick, MD, Chief Clinical Officer of TherapeuticsMD.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Tesaro and TherapeuticsMD

    NEW YORK, NY / ACCESSWIRE / May 29, 2018 / OPEC and major oil-producer Russia were considering an increase in supply, pressuring energy stocks lower. U.S. markets however posted weekly gains on Friday, ...

  • Business Wire2 months ago

    TherapeuticsMD Comments on Media Reports Regarding TX-004HR

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today commented on media reports that TX-004HR, the company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual activity (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause, has been approved by the U.S. Food and Drug Administration (FDA). As previously announced, the New Drug Application (NDA) for TX-004HR has a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2018.

  • Options Traders Expect Huge Moves in TherapeuticsMD (TXMD) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in TherapeuticsMD (TXMD) Stock

    Investors in TherapeuticsMD (TXMD) need to pay close attention to the stock based on moves in the options market lately.

  • Business Wire2 months ago

    TherapeuticsMD Announces Investor and Analyst Day on June 4

    TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the Company will host an Investor and Analyst Day on Monday, June 4, 2018, in New York City. The event will feature presentations by the TherapeuticsMD senior leadership team and industry experts to provide an overview of the company’s outlook and strategy for its two late-stage women’s health product candidates: TX-004HR for treatment of moderate-to-severe vaginal pain associated with sexual activity (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause, and TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS), due to menopause. The Prescription Drug User Fee Act (PDUFA) target action date for the completion of the U.S. Food and Drug Administration (FDA) review of the New Drug Application (NDA) for TX-004HR is May 29, 2018 and for TX-001HR is October 28, 2018.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of TXMD earnings conference call or presentation 3-May-18 8:30pm GMT

    Q1 2018 TherapeuticsMD Inc Earnings Call

  • See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about TherapeuticsMD Inc.

    TherapeuticsMD Inc NASDAQ/NGS:TXMD

  • Associated Press3 months ago

    TherapeuticsMD: 1Q Earnings Snapshot

    On a per-share basis, the Boca Raton, Florida-based company said it had a loss of 11 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Business Wire3 months ago

    TherapeuticsMD Announces First Quarter 2018 Financial Results

    TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced its financial results for the quarter ended March 31, 2018.